Ken Griffin Syndax Pharmaceuticals Inc Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $407,011 - $563,187	22,700 Added 72.99%	53,800 $1.04 Million
Q2 2024 Aug 14, 2024	SELL	$18.82 - $23.79 $425,332 - $537,654	-22,600 Reduced 42.09%	31,100 $638,000
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $1.58 Million - $1.97 Million	-80,100 Reduced 59.87%	53,700 $1.28 Million
Q4 2023 Feb 14, 2024	SELL	$11.39 - $21.67 $2.1 Million - $4 Million	-184,600 Reduced 57.98%	133,800 $2.89 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $4.58 Million - $6.87 Million	315,400 Added 10513.33%	318,400 $4.62 Million
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $251,550 - $290,030	-13,000 Reduced 81.25%	3,000 $62,000
Q1 2023 May 15, 2023	SELL	$20.66 - $28.98 $4,132 - $5,796	-200 Reduced 1.23%	16,000 $337,000
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $334,368 - $425,088	16,200 New	16,200 $412,000

228

88.4M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.